Skip to main content
Top
Published in: International Urology and Nephrology 6/2017

01-06-2017 | Urology - Original Paper

Neutrophil-to-lymphocyte ratio as an independent predictor for survival in patients with localized clear cell renal cell carcinoma after radiofrequency ablation: a propensity score matching analysis

Authors: Xiaofeng Chang, Fan Zhang, Tieshi Liu, Wei Wang, Hongqian Guo

Published in: International Urology and Nephrology | Issue 6/2017

Login to get access

Abstract

Objective

To investigate the role of neutrophil-to-lymphocyte ratio as a prognostic indicator in patients with localized clear cell renal cell carcinoma treated with radiofrequency ablation.

Patients and methods

We retrospectively analyzed data from patients with renal cell carcinoma who underwent radiofrequency ablation from 2006 to 2013. The Kaplan–Meier method was used to generate the survival curves according to different categories of neutrophil-to-lymphocyte ratio. Relationships between preoperative neutrophil-to-lymphocyte ratio or the change of neutrophil-to-lymphocyte ratio and survival were evaluated with multivariable Cox proportional hazards regression analysis. A propensity score matching analysis was carried out to avoid confounding bias.

Results

A total of 185 patients were included in present study. When stratified by preoperative neutrophil-to-lymphocyte ratio cutoff value of 2.79, 5-year recurrence-free survival, 5-year disease-free survival, and 5-year overall survival rates of neutrophil-to-lymphocyte ratio <2.79 versus ≥2.79 were 100, 98.5, and 99.2% versus 80.5, 72.6, and 90.6%, respectively (P < 0.001, P < 0.001, P = 0.003). In terms of propensity score matching analysis, 5-year recurrence-free survival, 5-year disease-free survival, and 5-year overall survival rates of neutrophil-to-lymphocyte ratio <2.79 versus ≥2.79 were 100, 97.9, and 100% versus 82.3, 73.4, and 89.4%, respectively (P = 0.003, P = 0.001, P = 0.022). When combining preoperative neutrophil-to-lymphocyte ratio with the change of neutrophil-to-lymphocyte ratio, patients with both preoperative neutrophil-to-lymphocyte ratio ≥2.79 and the change of neutrophil-to-lymphocyte ratio ≥0.40 had the worst disease-free survival. Results of multivariable analysis showed that preoperative neutrophil-to-lymphocyte ratio and the change of neutrophil-to-lymphocyte ratio correlated with cancer relapse remarkably.

Conclusions

High preoperative neutrophil-to-lymphocyte ratio and elevated postoperative neutrophil-to-lymphocyte ratio are associated with significant increase in risk of local recurrence as well as distant metastasis. The combination of neutrophil-to-lymphocyte ratio with the other prognostic indicators can be applied in the evaluation of relapse risk in patients with clear cell renal cell carcinoma after radiofrequency ablation.
Literature
1.
go back to reference Gupta K, Miller JD, Li JZ et al (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34(3):193–205CrossRefPubMed Gupta K, Miller JD, Li JZ et al (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34(3):193–205CrossRefPubMed
2.
go back to reference Ljungberg B, Bensalah K, Canfield S et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924CrossRefPubMed Ljungberg B, Bensalah K, Canfield S et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924CrossRefPubMed
3.
go back to reference Ma Y, Bedir S, Cadeddu JA et al (2014) Long-term outcomes in healthy adults after radiofrequency ablation of T1a renal tumours. BJU Int 113(1):51–55CrossRefPubMed Ma Y, Bedir S, Cadeddu JA et al (2014) Long-term outcomes in healthy adults after radiofrequency ablation of T1a renal tumours. BJU Int 113(1):51–55CrossRefPubMed
4.
go back to reference Chang X, Zhang F, Liu T et al (2015) Radio frequency ablation versus partial nephrectomy for clinical T1b renal cell carcinoma: long-term clinical and oncologic outcomes. J Urol 193(2):430–435CrossRefPubMed Chang X, Zhang F, Liu T et al (2015) Radio frequency ablation versus partial nephrectomy for clinical T1b renal cell carcinoma: long-term clinical and oncologic outcomes. J Urol 193(2):430–435CrossRefPubMed
5.
go back to reference Best SL, Park SK, Youssef RF et al (2012) Long-term outcomes of renal tumor radio frequency ablation stratified by tumor diameter: size matters. J Urol 187(4):1183–1189CrossRefPubMed Best SL, Park SK, Youssef RF et al (2012) Long-term outcomes of renal tumor radio frequency ablation stratified by tumor diameter: size matters. J Urol 187(4):1183–1189CrossRefPubMed
6.
go back to reference Psutka SP, Feldman AS, McDougal WS et al (2013) Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol 63(3):486–492CrossRefPubMed Psutka SP, Feldman AS, McDougal WS et al (2013) Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol 63(3):486–492CrossRefPubMed
7.
go back to reference Shuch BM, Lam JS, Belldegrun AS et al (2006) Prognostic factors in renal cell carcinoma. Semin Oncol 33(5):563–575CrossRefPubMed Shuch BM, Lam JS, Belldegrun AS et al (2006) Prognostic factors in renal cell carcinoma. Semin Oncol 33(5):563–575CrossRefPubMed
9.
go back to reference Luo Y, She DL, Xiong H et al (2015) Pretreatment neutrophil to lymphocyte ratio as a prognostic predictor of urologic tumors: a systematic review and meta-analysis. Medicine 94(40):e1670CrossRefPubMedPubMedCentral Luo Y, She DL, Xiong H et al (2015) Pretreatment neutrophil to lymphocyte ratio as a prognostic predictor of urologic tumors: a systematic review and meta-analysis. Medicine 94(40):e1670CrossRefPubMedPubMedCentral
10.
go back to reference Chua W, Charles KA, Baracos VE et al (2011) Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 104(8):1288–1295CrossRefPubMedPubMedCentral Chua W, Charles KA, Baracos VE et al (2011) Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 104(8):1288–1295CrossRefPubMedPubMedCentral
11.
go back to reference van Soest RJ, Templeton AJ, Vera-Badillo FE et al (2015) Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol 26(4):743–749CrossRefPubMed van Soest RJ, Templeton AJ, Vera-Badillo FE et al (2015) Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol 26(4):743–749CrossRefPubMed
12.
go back to reference Viers BR, Boorjian SA, Frank I et al (2014) Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol 66(6):1157–1164CrossRefPubMed Viers BR, Boorjian SA, Frank I et al (2014) Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol 66(6):1157–1164CrossRefPubMed
13.
go back to reference Ohno Y, Nakashima J, Ohori M et al (2010) Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol 184(3):873–878CrossRefPubMed Ohno Y, Nakashima J, Ohori M et al (2010) Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol 184(3):873–878CrossRefPubMed
14.
go back to reference Ohno Y, Nakashima J, Ohori M et al (2012) Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol 187(2):411–417CrossRefPubMed Ohno Y, Nakashima J, Ohori M et al (2012) Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol 187(2):411–417CrossRefPubMed
15.
go back to reference Templeton AJ, McNamara MG, Seruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124CrossRefPubMed Templeton AJ, McNamara MG, Seruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124CrossRefPubMed
16.
go back to reference Chang X, Ji C, Zhao X et al (2014) The application of R.E.N.A.L. nephrometry scoring system in predicting the complications after laparoscopic renal radiofrequency ablation. J Endourol 28(4):424–429CrossRefPubMed Chang X, Ji C, Zhao X et al (2014) The application of R.E.N.A.L. nephrometry scoring system in predicting the complications after laparoscopic renal radiofrequency ablation. J Endourol 28(4):424–429CrossRefPubMed
17.
go back to reference Zhao X, Wang W, Zhang S et al (2012) Improved outcome of percutaneous radiofrequency ablation in renal cell carcinoma: a retrospective study of intraoperative contrast-enhanced ultrasonography in 73 patients. Abdom Imaging 37(5):885–891CrossRefPubMed Zhao X, Wang W, Zhang S et al (2012) Improved outcome of percutaneous radiofrequency ablation in renal cell carcinoma: a retrospective study of intraoperative contrast-enhanced ultrasonography in 73 patients. Abdom Imaging 37(5):885–891CrossRefPubMed
18.
go back to reference Farrell MA, Charboneau WJ, DiMarco DS et al (2003) Imaging-guided radiofrequency ablation of solid renal tumors. Am J Roentgenol 180(6):1509–1513CrossRef Farrell MA, Charboneau WJ, DiMarco DS et al (2003) Imaging-guided radiofrequency ablation of solid renal tumors. Am J Roentgenol 180(6):1509–1513CrossRef
19.
go back to reference Park S, Anderson JK, Matsumoto ED et al (2006) Radiofrequency ablation of renal tumors: intermediate-term results. J Endourol 20(8):569–573CrossRefPubMed Park S, Anderson JK, Matsumoto ED et al (2006) Radiofrequency ablation of renal tumors: intermediate-term results. J Endourol 20(8):569–573CrossRefPubMed
20.
go back to reference Chu KF, Dupuy DE (2014) Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 14(3):199–208CrossRefPubMed Chu KF, Dupuy DE (2014) Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 14(3):199–208CrossRefPubMed
22.
go back to reference Petrie HT, Klassen LW, Kay HD (1985) Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 134(1):230–234PubMed Petrie HT, Klassen LW, Kay HD (1985) Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 134(1):230–234PubMed
23.
go back to reference de Martino M, Pantuck AJ, Hofbauer S et al (2013) Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol 190(6):1999–2004CrossRefPubMed de Martino M, Pantuck AJ, Hofbauer S et al (2013) Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol 190(6):1999–2004CrossRefPubMed
24.
go back to reference den Brok MH, Sutmuller RP, van der Voort R et al (2004) In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 64(11):4024–4029CrossRef den Brok MH, Sutmuller RP, van der Voort R et al (2004) In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 64(11):4024–4029CrossRef
25.
go back to reference Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2):205–214CrossRefPubMed Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2):205–214CrossRefPubMed
26.
go back to reference Zagoria RJ, Traver MA, Werle DM et al (2007) Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. Am J Roentgenol 189(2):429–436CrossRef Zagoria RJ, Traver MA, Werle DM et al (2007) Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. Am J Roentgenol 189(2):429–436CrossRef
27.
go back to reference Ferakis N, Bouropoulos C, Granitsas T et al (2010) Long-term results after computed-tomography-guided percutaneous radiofrequency ablation for small renal tumors. J Endourol 24(12):1909–1913CrossRefPubMed Ferakis N, Bouropoulos C, Granitsas T et al (2010) Long-term results after computed-tomography-guided percutaneous radiofrequency ablation for small renal tumors. J Endourol 24(12):1909–1913CrossRefPubMed
Metadata
Title
Neutrophil-to-lymphocyte ratio as an independent predictor for survival in patients with localized clear cell renal cell carcinoma after radiofrequency ablation: a propensity score matching analysis
Authors
Xiaofeng Chang
Fan Zhang
Tieshi Liu
Wei Wang
Hongqian Guo
Publication date
01-06-2017
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 6/2017
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-017-1554-6

Other articles of this Issue 6/2017

International Urology and Nephrology 6/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine